<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34192710</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>CEACAM5, KLK6, SLC35D3, POSTN, and MUC2 mRNA Analysis Improves Detection and Allows Characterization of Tumor Cells in Lymph Nodes of Patients Who Have Colon Cancer.</ArticleTitle><Pagination><StartPage>1354</StartPage><EndPage>1363</EndPage><MedlinePgn>1354-1363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002151</ELocationID><Abstract><AbstractText Label="BACKGROUND">Lymph node metastasis is the single most important prognostic risk factor for recurrence in patients with colon cancer who have undergone curative surgery. The routine method for detecting disseminated tumor cells in lymph nodes is microscopic examination of one or a few hematoxylin and eosin-stained tissue sections by a trained pathologist. This method, however, is insensitive mainly because less than 1% of the lymph node volume is examined, leading to misclassification.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to investigate whether analysis of a selected group of biomarker mRNAs improves detection and characterization of lymph node metastases/micrometastases compared with the routine method.</AbstractText><AbstractText Label="DESIGN">This study is a side-by-side comparison of biomarker mRNA analysis and histopathology of 185 lymph nodes from patients with colon cancer representing stages I to IV, and an investigation of the importance of lymph node tissue volume for tumor cell detection.</AbstractText><AbstractText Label="SETTINGS">This is a collaborative study between a high-volume central hospital and a preclinical university institution.</AbstractText><AbstractText Label="PATIENTS">Fifty-seven patients who had undergone tumor resection for colon cancer were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcomes measured were mRNA copies per 18S rRNA copy of CEACAM5, KLK6, SLC35D3, POSTN, and MUC2 by multiplex assay and metastases/micrometastases detected by histopathology.</AbstractText><AbstractText Label="RESULTS">The number of tumor cell-positive lymph nodes was 1.33-fold higher based on CEACAM5 mRNA levels compared with histopathological examination. Increasing the tissue volume analyzed for CEACAM5 levels from an 80-&#xb5;m section to half a lymph node increased the number of positive nodes from 34 of 107 to 80 of 107 (p &lt; 0.0001). Similarly, the number of positive nodes for the aggressiveness marker KLK6 increased from 9 of 107 to 24 of 107.</AbstractText><AbstractText Label="LIMITATIONS">Only a limited number of individual lymph nodes per patient was available for analysis.</AbstractText><AbstractText Label="CONCLUSIONS">mRNA analysis of CEACAM5, KLK6, and SLC35D3 improves the detection of tumor cells in lymph nodes from patients surgically treated for colon cancer, and, together with POSTN and MUC2, it further allows characterization of the tumor cells with respect to aggressiveness and the tumor cell environment. See Video Abstract at http://links.lww.com/DCR/B650.</AbstractText><AbstractText Label="EL ANLISIS DE ARNM DE CEACAM, KLK, SLCD, POSTN Y MUC MEJORA LA DETECCIN Y PERMITE LA CARACTERIZACIN DE CLULAS TUMORALES EN LOS GANGLIOS LINFTICOS DE PACIENTES CON CNCER DE COLON">ANTECEDENTES:Las met&#xe1;stasis en los ganglios linf&#xe1;ticos son el factor de riesgo pron&#xf3;stico m&#xe1;s importante de recurrencia en pacientes con c&#xe1;ncer de colon que se han sometido a cirug&#xed;a curativa. El m&#xe9;todo de rutina para detectar c&#xe9;lulas tumorales diseminadas en los ganglios linf&#xe1;ticos es el examen microsc&#xf3;pico de una o algunas secciones de tejido te&#xf1;idas con hematoxilina-eosina por un pat&#xf3;logo capacitado. Sin embargo, este m&#xe9;todo es insensible principalmente porque se examina menos del 1% del volumen de los ganglios linf&#xe1;ticos, lo que conduce a una clasificaci&#xf3;n err&#xf3;nea.OBJETIVO:Investigar si el an&#xe1;lisis de un grupo seleccionado de ARNm de biomarcadores mejora la detecci&#xf3;n y caracterizaci&#xf3;n de met&#xe1;stasis / micromet&#xe1;stasis en los ganglios linf&#xe1;ticos en comparaci&#xf3;n con el m&#xe9;todo de rutina.DISE&#xd1;O:Una comparaci&#xf3;n en paralelo del an&#xe1;lisis de ARNm de biomarcadores y la histopatolog&#xed;a de 185 ganglios linf&#xe1;ticos de pacientes con c&#xe1;ncer de colon que representan las etapas I-IV, e investigaci&#xf3;n de la importancia del volumen de tejido de los ganglios linf&#xe1;ticos para la detecci&#xf3;n de c&#xe9;lulas tumorales.ENTORNO CLINICO:Estudio colaborativo entre un hospital central de alto volumen y una instituci&#xf3;n universitaria precl&#xed;nica.PACIENTES:Cincuenta y siete pacientes que han sido sometidos a resecci&#xf3;n tumoral por c&#xe1;ncer de colon.PRINCIPALES MEDIDAS DE VALORACION:copias de ARNm / copia de ARNr 18S de CEACAM5, KLK6, SLC35D3, POSTN y MUC2 mediante an&#xe1;lisis m&#xfa;ltiple y met&#xe1;stasis / micromet&#xe1;stasis detectadas por histopatolog&#xed;a.RESULTADOS:El n&#xfa;mero de ganglios linf&#xe1;ticos con c&#xe9;lulas tumorales positivas fue 1,33 veces mayor seg&#xfa;n los niveles de ARNm de CEACAM5 en comparaci&#xf3;n con el examen histopatol&#xf3;gico. El aumento del volumen de tejido analizado para los niveles de CEACAM5 de una secci&#xf3;n de 80 &#xb5;m a la mitad de un ganglio linf&#xe1;tico aument&#xf3; el n&#xfa;mero de ganglios positivos de 34/107 a 80/107 (p &lt;0,0001). De manera similar, el n&#xfa;mero de nodos positivos para el marcador de agresividad KLK6 aument&#xf3; de 9/107 a 24/107.LIMITACIONES:Solo un n&#xfa;mero limitado de ganglios linf&#xe1;ticos individuales / paciente estuvo disponible para el an&#xe1;lisis.CONCLUSIONES:El an&#xe1;lisis de ARNm de CEACAM5, KLK6 y SLC35D3 mejora la detecci&#xf3;n de c&#xe9;lulas tumorales en los ganglios linf&#xe1;ticos de pacientes con c&#xe1;ncer de colon tratados quir&#xfa;rgicamente y, junto con POSTN y MUC2, permite adem&#xe1;s la caracterizaci&#xf3;n de las c&#xe9;lulas tumorales con respecto a la agresividad y el entorno celular tumoral. Consulte Video Resumen en http://links.lww.com/DCR/B650.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Lina M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Section of Infection and Immunology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HiloProbe AB, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindmark</LastName><ForeName>Gudrun E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, Helsingborg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Specialistl&#xe4;karna, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israelsson</LastName><ForeName>Anne C E</ForeName><Initials>ACE</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Section of Infection and Immunology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korkocic</LastName><ForeName>Dejan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Helsingborg Hospital, Helsingborg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammarstr&#xf6;m</LastName><ForeName>Sten G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Section of Infection and Immunology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammarstr&#xf6;m</LastName><ForeName>Marie-Louise K C</ForeName><Initials>MKC</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Section of Infection and Immunology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527875">CEACAM5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C524625">MUC2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009004">Monosaccharide Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055262">Mucin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C512835">POSTN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C103551">KLK6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D007610">Kallikreins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015815" MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007610" MajorTopicYN="N">Kallikreins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009004" MajorTopicYN="N">Monosaccharide Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055262" MajorTopicYN="N">Mucin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>20</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34192710</ArticleId><ArticleId IdType="pmc">PMC8492186</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002151</ArticleId><ArticleId IdType="pii">00003453-202111000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99:433&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374833</ArticleId></ArticleIdList></Reference><Reference><Citation>Iddings D, Bilchik A. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J Surg Oncol. 2007;96:671&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">18081169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007;9:563&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2049052</ArticleId><ArticleId IdType="pubmed">17916603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17237035</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;ckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54:5&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25430983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong ML, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016;8:179&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807319</ArticleId><ArticleId IdType="pubmed">27022445</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrill C, Carr NJ, Wilkinson-Smith E, Seel EH. Histopathological assessment of lymph nodes in colorectal carcinoma: does triple levelling detect significantly more metastases? J Clin Pathol. 2004;57:1165&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1770482</ArticleId><ArticleId IdType="pubmed">15509677</ArticleId></ArticleIdList></Reference><Reference><Citation>Weixler B, Warschkow R, G&#xfc;ller U, et al. . Isolated tumor cells in stage I &amp; II colon cancer patients are associated with significantly worse disease-free and overall survival. BMC Cancer. 2016;16:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754888</ArticleId><ArticleId IdType="pubmed">26879046</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25:1454&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">29616422</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;berg &#xc5;N, Lindmark GE, Israelsson AC, Hammarstr&#xf6;m SG, Hammarstr&#xf6;m ML. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAS. Int J Cancer. 2004;111:101&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">15185350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson L, Hammarstr&#xf6;m ML, Israelsson A, et al. . Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer. 2006;95:218&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2360623</ArticleId><ArticleId IdType="pubmed">16755296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson L, Israelsson A, &#xd6;berg &#xc5;, et al. . Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer. Int J Cancer. 2012;130:1833&#x2013;1843.</Citation><ArticleIdList><ArticleId IdType="pubmed">21618511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson L, Lindmark G, Israelsson A, et al. . Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer. Br J Cancer. 2012;107:150&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389417</ArticleId><ArticleId IdType="pubmed">22699826</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson L, Hammarstr&#xf6;m ML, Israelsson A, Lindmark G, Hammarstr&#xf6;m S. Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis. PLoS One. 2020;15:e0229007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015415</ArticleId><ArticleId IdType="pubmed">32049988</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Luo D, Li Q, Zhu J, Li X. Evaluating the effect of lymph node status on survival in large colon cancer. Front Oncol. 2018;8:602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298250</ArticleId><ArticleId IdType="pubmed">30619744</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahlgren A, Hammarstr&#xf6;m S, Danielsson A, Hammarstr&#xf6;m ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol. 2003;131:90&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808590</ArticleId><ArticleId IdType="pubmed">12519391</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>